Gain-of-Function Research: Summary of the Second Symposium, March 10-11, 2016.
...
Philip R. Dormitzer is vice president and chief scientific officer for viral vaccines in the Pfizer Vaccine Research and Development Unit. He is a board certified internal medicine physician. After studying anthropology at Harvard College and carrying out a field study of the Efe Pygmies in the Ituri Forest of Zaire, he completed his M.D. and Ph.D. in Cancer Biology at Stanford University. Dr. Dormitzer completed house-staff training in Internal Medicine at Massachusetts General Hospital and a fellowship in the Harvard Combined Infectious Diseases Training Program. As an assistant professor of pediatrics at Harvard Medical School, Dr. Dormitzer led a structural virology laboratory. The Dormitzer group and its collaborators determined the structures of the rotavirus neutralization antigens by nuclear magnetic resonance spectroscopy, X-ray crystallography, and near atomic resolution electron cryomicroscopy. From 2007-2015 Dr. Dormitzer held a series of positions at Novartis Vaccines and Diagnostics, and was global head of research and vice president at a successor company, Novartis Influenza Vaccines. His teams' research and development programs included vaccines targeting influenza, respiratory syncytial virus, cytomegalovirus, HIV, and parvovirus B19. In 2009, he led the research component of the Novartis response to the H1N1 influenza pandemic, supporting the development and licensure of three pandemic influenza vaccines in the most rapid vaccine response in history. In a Biomedical Advanced Research and Development Authority–funded collaboration with the J. Craig Venter Institute and Synthetic Genomics Vaccines, Inc., the Novartis influenza vaccine research team developed a process to synthesize influenza vaccine seed viruses and deployed the technology in response to the H7N9 influenza outbreak in China. The team's other technology platforms included structurally engineered antigens, adjuvants that target toll-like receptors, and self-replicating messenger RNA vaccines.
...